FerGene has been spun off by Ferring Pharmaceuticals to bring a gene therapy for bladder cancer to market, and Ferring itself is supplying $170m of the cash.

Switzerland-based biopharmaceutical group Ferring Pharmaceuticals has spun off a gene therapy company called FerGene with $570m in funding. Ferring itself is providing up to $170m while the remaining $400m will be invested by Blackstone Life Sciences, a specialist investment platform owned by asset management firm Blackstone. FerGene will concentrate on the late-stage development and commercialisation…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.